Orion Oyj
ISIN: FI0009014369 | Ticker: ORNAV | LEI: 74370029VAHCXDR7B745
Country: Finland
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are oncology and pain.
Orion's customers are mainly healthcare service providers and professionals such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centres, clinics and laboratories. Consumers with pets are another important customer group.
Orion's main market is Finland, where it is the clear market leader. Orion’s products are marketed in over a hundred countries, and the Group's own human pharmaceuticals sales organisation covers almost all key European markets and a few Southeast Asian countries. In other markets Orion’s products are sold by several collaboration partners.
Worldwide
HeadquartersOrionintie 1A, 2200 Espoo – Finland
| Line item in (eur) | 02.01.2019 | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Assets | N/A | 1,035,700,000.00 | 1,115,600,000.00 | 1,114,000,000.00 | 1,503,600,000.00 |
| Noncurrent Assets | N/A | 435,600,000.00 | 371,800,000.00 | 423,700,000.00 | 624,900,000.00 |
| Property Plant And Equipment | N/A | 320,900,000.00 | 319,600,000.00 | 332,600,000.00 | 373,300,000.00 |
| Goodwill | N/A | 13,500,000.00 | 13,500,000.00 | 13,500,000.00 | 87,200,000.00 |
| Copyrights Patents And Other Industrial Property Rights Service And Operating Rights | N/A | 34,800,000.00 | 26,800,000.00 | 53,000,000.00 | 100,000,000.00 |
| Other Intangible Assets | N/A | 2,800,000.00 | 2,700,000.00 | 2,500,000.00 | 3,800,000.00 |
| Investments In Associates Accounted For Using Equity Method | N/A | 100,000.00 | 100,000.00 | 100,000.00 | 100,000.00 |
| Other Noncurrent Receivables | N/A | 800,000.00 | 500,000.00 | 300,000.00 | 1,000,000.00 |
| Deferred Tax Assets | N/A | 6,800,000.00 | 8,400,000.00 | 6,600,000.00 | 3,100,000.00 |
| Noncurrent Recognised Assets Defined Benefit Plan | N/A | 55,800,000.00 | N/A | 15,000,000.00 | 56,200,000.00 |
| Noncurrent Investments Other Than Investments Accounted For Using Equity Method | N/A | 200,000.00 | 200,000.00 | 200,000.00 | 200,000.00 |
| Current Assets | N/A | 600,100,000.00 | 743,700,000.00 | 690,300,000.00 | 878,700,000.00 |
| Inventories | N/A | 230,300,000.00 | 258,100,000.00 | 265,200,000.00 | 315,600,000.00 |
| Current Trade Receivables | N/A | 196,500,000.00 | 157,400,000.00 | 174,800,000.00 | 180,700,000.00 |
| Other Current Receivables | N/A | 24,300,000.00 | 33,900,000.00 | 30,200,000.00 | 44,800,000.00 |
| Current Tax Assets Current | N/A | N/A | N/A | 3,300,000.00 | 4,900,000.00 |
| Cash and cash equivalents | N/A | 114,000,000.00 | 294,400,000.00 | 216,700,000.00 | 332,600,000.00 |
| Equity And Liabilities | N/A | 1,035,700,000.00 | 1,115,600,000.00 | 1,114,000,000.00 | 1,503,600,000.00 |
| Equity | 772,900,000.00 | 779,400,000.00 | 731,300,000.00 | 747,900,000.00 | 908,100,000.00 |
| Issued Capital | N/A | 92,200,000.00 | 92,200,000.00 | 92,200,000.00 | 92,200,000.00 |
| Retained Earnings | N/A | 684,200,000.00 | 635,700,000.00 | N/A | N/A |
| Other Reserves | N/A | 3,000,000.00 | 3,400,000.00 | N/A | N/A |
| Equity Attributable To Owners Of Parent | N/A | 779,400,000.00 | 731,300,000.00 | 747,900,000.00 | 908,100,000.00 |
| Liabilities | N/A | 256,300,000.00 | 384,200,000.00 | 366,100,000.00 | 595,500,000.00 |
| Noncurrent Liabilities | N/A | 68,800,000.00 | 170,100,000.00 | 156,900,000.00 | 320,200,000.00 |
| Noncurrent Provisions | N/A | 400,000.00 | 400,000.00 | 400,000.00 | N/A |
| Other Longterm Provisions | N/A | N/A | N/A | 400,000.00 | 600,000.00 |
| Deferred Tax Liabilities | N/A | 41,200,000.00 | 29,300,000.00 | 34,000,000.00 | 42,200,000.00 |
| Noncurrent Recognised Liabilities Defined Benefit Plan | N/A | 3,400,000.00 | 19,900,000.00 | 4,900,000.00 | 3,000,000.00 |
| Other Noncurrent Liabilities | N/A | 17,100,000.00 | 15,000,000.00 | 13,000,000.00 | 77,700,000.00 |
| Longterm Borrowings | N/A | 6,700,000.00 | 105,500,000.00 | 104,700,000.00 | 196,800,000.00 |
| Current Liabilities | N/A | 187,500,000.00 | 214,100,000.00 | 209,200,000.00 | 275,400,000.00 |
| Current Provisions | N/A | N/A | N/A | 0.00 | 100,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 79,000,000.00 | 86,700,000.00 | 89,600,000.00 | 114,400,000.00 |
| Current Tax Liabilities Current | N/A | 2,600,000.00 | 2,500,000.00 | 6,800,000.00 | 1,400,000.00 |
| Other Current Liabilities | N/A | 102,600,000.00 | 121,800,000.00 | 109,000,000.00 | 142,400,000.00 |
| Line item in (eur) | 01.01.2019/ 01.01.2020 |
01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|---|
| Revenue | 1,051,000,000.00 | 1,078,100,000.00 | 1,041,000,000.00 | 1,340,600,000.00 |
| Employee Benefits Expense | 217,100,000.00 | 227,000,000.00 | 231,000,000.00 | N/A |
| Depreciation Amortisation And Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | 56,100,000.00 | 56,500,000.00 | 45,800,000.00 | N/A |
| Profit Loss From Operating Activities | 252,800,000.00 | 280,100,000.00 | 243,300,000.00 | 439,600,000.00 |
| Finance Income | 700,000.00 | 200,000.00 | N/A | N/A |
| Finance Costs | 2,600,000.00 | 2,000,000.00 | N/A | N/A |
| Profit Loss Before Tax | 250,800,000.00 | 278,300,000.00 | 242,300,000.00 | 440,300,000.00 |
| Income Tax Expense Continuing Operations | 50,500,000.00 | 58,400,000.00 | 48,500,000.00 | 90,800,000.00 |
| Profit (loss) | 200,400,000.00 | 219,900,000.00 | 193,800,000.00 | 349,500,000.00 |
| Profit Loss Attributable To Owners Of Parent | 200,400,000.00 | 219,900,000.00 | 193,800,000.00 | 349,500,000.00 |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | 200,400,000.00 | 219,900,000.00 | 193,800,000.00 | 349,500,000.00 |
| Adjustments For Reconcile Profit Loss | 58,700,000.00 | 58,200,000.00 | 50,200,000.00 | 113,600,000.00 |
| Adjustments For Decrease Increase In Inventories | -8,000,000.00 | -29,000,000.00 | -6,900,000.00 | -4,100,000.00 |
| Adjustments For Provisions | 0.00 | 0.00 | 100,000.00 | 200,000.00 |
| Adjustments For Unrealised Foreign Exchange Losses Gains | -400,000.00 | 700,000.00 | -400,000.00 | 400,000.00 |
| Adjustments For Losses Gains On Disposal Of Noncurrent Assets | N/A | 0.00 | -3,900,000.00 | -100,000.00 |
| Other Adjustments To Reconcile Profit Loss | 600,000.00 | 1,300,000.00 | 1,400,000.00 | 63,600,000.00 |
| Adjustments For Reconcile Profit Loss | 58,700,000.00 | 58,200,000.00 | 50,200,000.00 | 113,600,000.00 |
| Dividends Received Classified As Operating Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flows From Used In Operating Activities | 270,800,000.00 | 299,100,000.00 | 215,700,000.00 | 434,400,000.00 |
| Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | 1,400,000.00 | N/A | N/A | N/A |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | N/A | N/A | 82,000,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | 28,700,000.00 | 34,000,000.00 | 47,000,000.00 | 56,500,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | 7,500,000.00 | 6,700,000.00 | 38,000,000.00 | 16,600,000.00 |
| Cash Flows From Used In Investing Activities | -34,000,000.00 | -39,700,000.00 | -80,200,000.00 | -154,300,000.00 |
| Payments To Acquire Or Redeem Entitys Shares | 7,400,000.00 | N/A | N/A | 17,900,000.00 |
| Dividends Paid Classified As Financing Activities | 211,200,000.00 | 211,100,000.00 | 211,200,000.00 | 211,200,000.00 |
| Cash Flows From Used In Financing Activities | -371,400,000.00 | -115,100,000.00 | -214,800,000.00 | -159,800,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | -134,500,000.00 | 144,300,000.00 | -79,300,000.00 | 120,400,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | -100,000.00 | 1,100,000.00 | 1,600,000.00 | -4,400,000.00 |
| Cash and cash equivalents | 114,000,000.00 | 294,400,000.00 | 216,700,000.00 | 332,600,000.00 |
Please note that some sums might not add up.
FI0009014369
LEI74370029VAHCXDR7B745
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryOMX Helsinki 25
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.